The Effects of Cannabis (Marijuana) on the Brain & Body

Huberman opens by defining the subject broadly: cannabis, also called marijuana, contains many compounds that act on brain and body, and the episode will cover THC, CBD, sativa, indica and hybrid strains, and even the newer type one, type two and type three nomenclature. The opening also sets a constraint that shapes everything afterward: legality varies enormously by country, state and region, and listeners are responsible for knowing the law where they live and travel. The promised picture is deliberately two-sided, covering where specific compounds can be extremely useful in treating some ailments and where they can be extremely dangerous, particularly for individuals with a preexisting genetic propensity for psychosis.

The agenda is unusually wide for a single episode. It includes cannabis in anxiety and depression, with both positive and negative effects, sex differences between women and men, and the contested topic of creativity, framed through convergent and divergent thinking and the memory systems those modes rely on. Huberman also signals that the discussion will be methodological rather than merely descriptive: he intends to read from specific papers and examine statistics and the particular populations studied, because the same dosage can be immensely beneficial to one group and entirely detrimental to another.

The variables he lists are dosage, meaning the concentration of THC relative to CBD; frequency, from daily and multiple-times-per-day use through weekly, monthly or occasional use; profession, since some jobs tolerate cognitive alteration far less than others; genetic predisposition; sex differences; and hormone effects. He then names what he considers the decisive factor, calling age 'the most important variable in determining whether or not cannabis is right or wrong for you' at the point of starting, continuing or ceasing use. The stated promise is a thorough account of mechanisms, benefits, hazards and individual fit, not a verdict.

But I do try to be thorough for your sake.

The strain discussion starts with genetics rather than effects. Cannabis plants come in different genetic strains, and growers hybridize them through grafting or seed combinations, much as animals with different genetic backgrounds are crossed. Naturally occurring variation also exists, and the episode distinguishes sativa, indica, a less-discussed variety called ruderalis, and hybrids of all three. The plant contains multiple psychoactive compounds; THC, or delta-9-tetrahydrocannabinol, is described as the most powerful, but it is only one of more than 70 psychoactive compounds, many of which have not been studied in isolation.

CBD, or cannabidiol, is presented as a compound used for pain and anxiety management and other medicinal purposes, with efficacy to be examined later, along with possible dangers that depend on sourcing and dose. CBN, or cannabinol, receives less attention but is included because it is relevant to the discussion. The broader count is more than 400 biologically active compounds, some psychoactive and some not, which Huberman uses to argue that the plant remains a vast and incompletely mapped research landscape. The episode therefore commits to separating what is known from what is still an open mystery.

Among the three major strains, ruderalis is effectively set aside because it is rarely consumed for medicinal or recreational purposes. Sativa and indica are distinguished first by plant architecture: at their extremes, sativa is taller with a longer stalk and longer leaves, while indica is shorter and stouter. Huberman argues that this is not cosmetic, because growth pattern, sunlight capture and interactions among plants influence how psychoactive compounds are distributed across leaves and buds. Consumption is also defined broadly to include smoking, not just edibles, with heat liberating compounds that are absorbed through lung vasculature, enter the bloodstream and cross the blood-brain barrier.

The familiar sativa-indica contrast then gets both stated and qualified. Sativa varieties are described as stimulant-like, producing invigoration, alertness, talkativeness, reduced susceptibility to pain and noxious stimuli, and a 'head-biased' high. Huberman explicitly flags that reports of heightened focus and creativity may reflect perceived rather than actual gains, and that subjective effects vary by individual. Indica is described as more full-bodied, sedative and relaxing, often used for sleep or anxiety relief. The mnemonic offered is 'indica couch', attributed to a friend who consumed marijuana daily for about 20 years before quitting four or five years ago.

Hybrids complicate the picture because growers can produce ratios such as 25 percent sativa and 75 percent indica, 50/50 or 90/10. Huberman credits plant genetics for making these combinations efficient and for generating nuanced effects, and notes that a new nomenclature has emerged alongside the old one. The type one, type two and type three labels cut across sativa, indica and hybrid categories and refer to the ratio of THC to CBD. Type one is THC dominant, type two is closer to equal ratios, and type three is high in CBD with very little THC. Crucially, these types are produced by hybridization, not by CRISPR-style gene editing, and the ratio is presented as a major predictor of a strain's effect.

Before returning to cannabis, Huberman deliberately sets the plant aside and asks a more basic question: why should any of these compounds affect us at all? The answer is built through the nicotine analogy. Nicotine from tobacco binds nicotinic receptors with high affinity, but those receptors exist because the body produces acetylcholine, which binds them at lower strength. In the same way, humans have cannabinoid receptors from very early in development because the body produces endogenous cannabinoids. The receptor is described as a parking spot and the ligand as the chemical that parks there and triggers biological effects.

The naming is treated as a trap. Calling them cannabinoid receptors makes it sound as though they evolved to bind cannabis, just as nicotinic receptors sound designed for tobacco, but Huberman insists that brains and bodies evolved to use internal chemicals. THC, CBD and other plant compounds bind the same receptors with much greater affinity and exert vastly greater potency on mood and perception than the endogenous ligands do. The hormone analogy makes the point concrete: everyone produces testosterone and estrogen to varying degrees, and synthetic derivatives such as Dianabol can bind androgen receptors with far greater affinity and produce supraphysiological effects that endogenous release would never achieve.

From this, Huberman attacks a common inference: because cannabis is a plant and because we have receptors for it, the plant must be safer or more appropriate for us. He calls that reasoning false, while explicitly denying that cannabis is always a bad idea. Some populations may use it relatively safely recreationally, he says, and others may be endangered by it recreationally or medicinally. The receptor's existence is not evidence of purpose; nicotinic receptors are not there because nicotine is good for us, but because internal compounds bind them from time to time.

The mechanistic consequence is central to the episode's account of dependence. THC and CBD bind endogenous cannabinoid receptors with thousandfold greater potency, so the body's own cannabinoids are outcompeted and get little opportunity to interact with those receptors. When cannabis is removed, the receptors are no longer stimulated to the usual degree and the endogenous ligands cannot compensate, which helps explain heightened anxiety, disrupted mood and disrupted brain state after cessation. Huberman frames this not as an argument that cannabis is all bad, but as an explanation for why it can be enormously effective in some contexts and a source of massive suffering in others.

The two main endogenous cannabinoids are anandamide, abbreviated EAE in the episode, and arachidonoyl glycerol, abbreviated 2-AG. Huberman lumps them together for simplicity but invites listeners to pursue the distinction. The relevant anatomy is standard synaptic transmission: presynaptic neurons package neurotransmitter in vesicles, electrical stimulation causes fusion and release into the synaptic cleft, and the transmitter parks on receptors on the postsynaptic side, producing excitation or inhibition. What makes cannabinoids unusual is the direction of travel, which the next section develops.

Endogenous cannabinoids are released from the postsynaptic side and travel backward, or retrogradely, to the presynaptic neuron, where they bind receptors and change the probability of neurotransmitter release. In simple terms, they tend to decrease that probability and act as a brake on communication, not silencing it completely but adjusting its level with nuance. This creates an apparent paradox: cannabis use reliably disrupts short-term memory, and Huberman says 'there is essentially zero debate as to whether or not that occurs', yet endogenous cannabinoids can also strengthen connections through long-term potentiation and weaken them through long-term depression.

He is careful to define long-term depression as a change in the probability that one neuron will stimulate another, not as the psychological illness. The metaphor is a phone's text chain: potentiation puts a contact at the top, while depression effectively blocks the number. The larger message is that endogenous cannabinoid signaling is context-dependent and directionally mixed, sometimes increasing communication and sometimes decreasing it, which makes any simple story about cannabis 'turning the brain up' or 'turning it down' inadequate.